Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms

Xin Chen, Xianping Shi, Chong Zhao, Xiaofen Li, Xiaoying Lan, Shouting Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, Dan Zang, Wenbin Song, Quentin Liu, Bing Z. Carter, Q. Ping Dou, Xuejun Wang, Jinbao Liu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors (TKI). Therefore it is urgent to search for new measures to overcome TKI-resistance. Auranofin (AF), clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer. In contrast to the reports that AF induces apoptosis by increasing intracellular reactive oxygen species (ROS) levels via inhibiting thioredoxin reductase, our recent study revealed that AF-induced apoptosis depends on inhibition of proteasomal deubiquitinases (UCHL5 and USP14). Here we report that (i) AF induces apoptosis in both Bcr-Abl wild-type cells and Bcr-Abl-T315I mutation cells and inhibits the growth of IM-resistant Bcr-Abl-T315I xenografts in vivo; (ii) AF inhibits Bcr-Abl through both downregulation of Bcr-Abl gene expression and Bcr-Abl cleavage mediated by proteasome inhibition-induced caspase activation; (iii) proteasome inhibition but not ROS is required for AF-induced caspase activation and apoptosis. These findings support that AF overcomes IM resistance through both Bcr/Abl-dependent and -independent mechanisms, providing great clinical significance for cancer treatment.

Original languageEnglish (US)
Pages (from-to)9118-9132
Number of pages15
JournalOncotarget
Volume5
Issue number19
DOIs
StatePublished - Jan 1 2014

Fingerprint

Auranofin
Antirheumatic Agents
Myeloid Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptosis
Proteasome Endopeptidase Complex
Caspases
Protein-Tyrosine Kinases
Reactive Oxygen Species
abl Genes
Thioredoxin-Disulfide Reductase
Phase II Clinical Trials
Mutation
Rheumatic Fever
United States Food and Drug Administration
Imatinib Mesylate
Heterografts
Neoplasms
Down-Regulation
Gene Expression

Keywords

  • Auranofin
  • Bcr-Abl
  • Chronic myelogenous leukemia
  • Imatinib resistance
  • Proteasome

ASJC Scopus subject areas

  • Oncology

Cite this

Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. / Chen, Xin; Shi, Xianping; Zhao, Chong; Li, Xiaofen; Lan, Xiaoying; Liu, Shouting; Huang, Hongbiao; Liu, Ningning; Liao, Siyan; Zang, Dan; Song, Wenbin; Liu, Quentin; Carter, Bing Z.; Ping Dou, Q.; Wang, Xuejun; Liu, Jinbao.

In: Oncotarget, Vol. 5, No. 19, 01.01.2014, p. 9118-9132.

Research output: Contribution to journalArticle

Chen, X, Shi, X, Zhao, C, Li, X, Lan, X, Liu, S, Huang, H, Liu, N, Liao, S, Zang, D, Song, W, Liu, Q, Carter, BZ, Ping Dou, Q, Wang, X & Liu, J 2014, 'Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms', Oncotarget, vol. 5, no. 19, pp. 9118-9132. https://doi.org/10.18632/oncotarget.2361
Chen, Xin ; Shi, Xianping ; Zhao, Chong ; Li, Xiaofen ; Lan, Xiaoying ; Liu, Shouting ; Huang, Hongbiao ; Liu, Ningning ; Liao, Siyan ; Zang, Dan ; Song, Wenbin ; Liu, Quentin ; Carter, Bing Z. ; Ping Dou, Q. ; Wang, Xuejun ; Liu, Jinbao. / Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. In: Oncotarget. 2014 ; Vol. 5, No. 19. pp. 9118-9132.
@article{3cdb31e81bb84ac597c1953b59b33c7b,
title = "Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms",
abstract = "Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors (TKI). Therefore it is urgent to search for new measures to overcome TKI-resistance. Auranofin (AF), clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer. In contrast to the reports that AF induces apoptosis by increasing intracellular reactive oxygen species (ROS) levels via inhibiting thioredoxin reductase, our recent study revealed that AF-induced apoptosis depends on inhibition of proteasomal deubiquitinases (UCHL5 and USP14). Here we report that (i) AF induces apoptosis in both Bcr-Abl wild-type cells and Bcr-Abl-T315I mutation cells and inhibits the growth of IM-resistant Bcr-Abl-T315I xenografts in vivo; (ii) AF inhibits Bcr-Abl through both downregulation of Bcr-Abl gene expression and Bcr-Abl cleavage mediated by proteasome inhibition-induced caspase activation; (iii) proteasome inhibition but not ROS is required for AF-induced caspase activation and apoptosis. These findings support that AF overcomes IM resistance through both Bcr/Abl-dependent and -independent mechanisms, providing great clinical significance for cancer treatment.",
keywords = "Auranofin, Bcr-Abl, Chronic myelogenous leukemia, Imatinib resistance, Proteasome",
author = "Xin Chen and Xianping Shi and Chong Zhao and Xiaofen Li and Xiaoying Lan and Shouting Liu and Hongbiao Huang and Ningning Liu and Siyan Liao and Dan Zang and Wenbin Song and Quentin Liu and Carter, {Bing Z.} and {Ping Dou}, Q. and Xuejun Wang and Jinbao Liu",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2361",
language = "English (US)",
volume = "5",
pages = "9118--9132",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "19",

}

TY - JOUR

T1 - Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms

AU - Chen, Xin

AU - Shi, Xianping

AU - Zhao, Chong

AU - Li, Xiaofen

AU - Lan, Xiaoying

AU - Liu, Shouting

AU - Huang, Hongbiao

AU - Liu, Ningning

AU - Liao, Siyan

AU - Zang, Dan

AU - Song, Wenbin

AU - Liu, Quentin

AU - Carter, Bing Z.

AU - Ping Dou, Q.

AU - Wang, Xuejun

AU - Liu, Jinbao

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors (TKI). Therefore it is urgent to search for new measures to overcome TKI-resistance. Auranofin (AF), clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer. In contrast to the reports that AF induces apoptosis by increasing intracellular reactive oxygen species (ROS) levels via inhibiting thioredoxin reductase, our recent study revealed that AF-induced apoptosis depends on inhibition of proteasomal deubiquitinases (UCHL5 and USP14). Here we report that (i) AF induces apoptosis in both Bcr-Abl wild-type cells and Bcr-Abl-T315I mutation cells and inhibits the growth of IM-resistant Bcr-Abl-T315I xenografts in vivo; (ii) AF inhibits Bcr-Abl through both downregulation of Bcr-Abl gene expression and Bcr-Abl cleavage mediated by proteasome inhibition-induced caspase activation; (iii) proteasome inhibition but not ROS is required for AF-induced caspase activation and apoptosis. These findings support that AF overcomes IM resistance through both Bcr/Abl-dependent and -independent mechanisms, providing great clinical significance for cancer treatment.

AB - Resistance to Imatinib mesylate (IM) is an emerging problem for patients with chronic myelogenous leukemia (CML). T315I mutation in the Bcr-Abl is the predominant mechanism of the acquired resistance to IM and second generation tyrosine kinase inhibitors (TKI). Therefore it is urgent to search for new measures to overcome TKI-resistance. Auranofin (AF), clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer. In contrast to the reports that AF induces apoptosis by increasing intracellular reactive oxygen species (ROS) levels via inhibiting thioredoxin reductase, our recent study revealed that AF-induced apoptosis depends on inhibition of proteasomal deubiquitinases (UCHL5 and USP14). Here we report that (i) AF induces apoptosis in both Bcr-Abl wild-type cells and Bcr-Abl-T315I mutation cells and inhibits the growth of IM-resistant Bcr-Abl-T315I xenografts in vivo; (ii) AF inhibits Bcr-Abl through both downregulation of Bcr-Abl gene expression and Bcr-Abl cleavage mediated by proteasome inhibition-induced caspase activation; (iii) proteasome inhibition but not ROS is required for AF-induced caspase activation and apoptosis. These findings support that AF overcomes IM resistance through both Bcr/Abl-dependent and -independent mechanisms, providing great clinical significance for cancer treatment.

KW - Auranofin

KW - Bcr-Abl

KW - Chronic myelogenous leukemia

KW - Imatinib resistance

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=84910065189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910065189&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2361

DO - 10.18632/oncotarget.2361

M3 - Article

VL - 5

SP - 9118

EP - 9132

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 19

ER -